Ting Liu

Mrs. Ting Liu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
TLTing Liu
Ting Liu
KYKun Yang
Kun Yang
JCJiamin Chen
Jiamin Chen
LQLiming Qi
Liming Qi
XZXingang Zhou
Xingang Zhou
PWPeng Wang
Peng Wang
KIF18A belongs to the Kinesin family, which participates in the occurrence and progression of tumors. However, few pan-cancer analyses have been performed on KIF18A to date. We used multiple public databases such as TIMER, The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Human Protein Atlas (HPA) to explore KIF18A mRNA expression in 33 tumors. We performed immunohistochemistry on liver cancer and pancreatic cancer tissues and corresponding normal tissues to examine the expression of KIF18A protein. Univariate Cox regression and Kaplan–Meier survival analysis were applied to detect the effect of KIF18A on overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) of patients with these tumors. Subsequently, we explored KIF18A gene alterations in different tumor tissues using cBioPortal. The relationship between KIF18A and clinical characteristics, tumor microenvironment (TME), immune regulatory genes, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repairs (MMRs), DNA methylation, RNA methylation, and drug sensitivity was applied for further study using the R language. Gene Set Enrichment Analysis (GSEA) was utilized to explore the molecular mechanism of KIF18A. Bioinformatic analysis and immunohistochemical experiments confirmed that KIF18A was up-regulated in 27 tumors and was correlated with the T stage, N stage, pathological stage, histological grade, and Ki-67 index in many cancers. The overexpression of KIF18A had poor OS, DSS, and PFI in adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), brain lower-grade glioma (LGG), liver cancer (LIHC), lung adenocarcinoma (LUAD), and pancreatic cancer (PAAD). Univariate and multivariate regression analysis confirmed KIF18A as an independent prognostic factor for LIHC and PAAD. The mutation frequency of KIF18A is the highest in endometrial cancer. KIF18A expression levels were positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI, MMRs, DNA methylation, RNA methylation, and drug sensitivity in certain cancers. In addition, we discovered that KIF18A participated in the cell cycle at the single-cell level and GSEA analysis for most cancers. These findings suggested that KIF18A could be regarded as a latent prognostic marker and a new target for cancer immunological therapy.

16 February 2024 in Cellular Signalling
Verified
Journal Article
Open access
WYWei Yang
Wei Yang
ZLZhidong Liu
Zhidong Liu
TLTing Liu
Ting Liu
CANT1, calcium-activated nucleotidase 1, was reported to be upregulated in certain tumors. However, the function mechanism of CANT1 in pan-cancer is still unclear. We utilized the Cancer Genome Atlas Program (TCGA) and UALCAN databases to analyze CANT1 expression at the level of mRNA, protein, and promoter methylation in pan-cancer, and the cBioportal database to study the frequency of gene changes for CANT1. Wilcoxon test was applied to discuss the correlation between CANT1 and clinicopathological features in different tumor types. The prognosis of CANT1 in pan-cancer was discussed by Cox regression. Spearman analysis was applied to discuss the relationship of CANT1 with tumor mutation burden(TMB), microsatellite instability(MSI), immune cell infiltration, and immune checkpoints. The association between CANT1 expression and drug sensitivity for pan-cancer was investigated by the GSCALite database. In addition, we collected 40 cases of lung adenocarcinoma (LUAD) and adjacent normal tissues for immunohistochemical staining and investigated the relationship between CANT1 and clinicopathology and prognosis in LUAD. Finally, the molecular pathways involved in CANT1-related genes in LUAD were analyzed by gene set enrichment analysis(GSEA). The CANT1 mRNA level was significant higher in 14 tumors, and CANT1 protein level was significant higher in 7 tumors compared with normal tissues. CANT1 expression was linked with the T stage, N stage, and pathological stage in some tumors, and overexpression CANT1 was associated with adverse overall survival(OS) and disease-specific survival(DSS) in kidney renal papillary cell carcinoma(KIRP), brain lower grade glioma(LGG), and LUAD. By Spearman correlation analysis, the results showed that CANT1 had a positive correlation with TMB and MSI in bladder urothelial carcinoma(BLCA), breast invasive carcinoma(BRCA), esophageal carcinoma(ESCA), LGG, and sarcoma(SARC). Furthermore, CANT1 was related to immune cell infiltration and immune checkpoints in several cancers. Drug sensitivity analysis suggested that CANT1 was inversely linked with three drugs. Immunohistochemical staining analysis showed that CANT1 expression was higher in LUAD than in normal tissues, and was related to N stage and pathological stage. Survival curves showed that CANT1 overexpression had poor OS and DSS. Time-dependent ROC curves revealed that the 1-year, 5-year, and 10-year OS and DSS in LUAD were above 0.5. CANT1-related genes in LUAD mainly participated in the pathway of dorso ventral axis formation, small cell lung cancer, DNA replication, O-glycan biosynthesis, and cell cycle. CANT1 is considered a potential marker for prognosis in several tumors, and a promising target for tumor immunological treatment.

21 June 2025 in 3 Biotech
Verified
Journal Article
Open access
PDF file
XZXuan Zhou
Xuan Zhou
YPYue Pan
Yue Pan
HLHong Li
Hong Li
YSYi-Fei Sun
Yi-Fei Sun
YLYu-Jun Li
Yu-Jun Li
TLTing Liu
Ting Liu
Anosmin-1 (ANOS1) is an extracellular matrix (ECM)-related glycoprotein that is highly expressed in a variety of tumors. However, the specific role and mechanism of ANOS1 in advanced gastric cancer (GC) and its correlation with epithelial–mesenchymal transition (EMT) are not well understood, despite ongoing research into the expression of ANOS1 and its impact on clinical outcomes. The ANOS1 expression and clinical data were acquired from The Cancer Genome Atlas (TCGA) database to analyze the differential expression of ANOS1 and its prognostic impact in advanced gastric cancer. The expression of ANOS1 and E-cadherin was detected using immunohistochemical (IHC) techniques in 99 cases of advanced gastric cancer (GC) tissues and their adjacent normal tissues. Subsequently, the correlation of ANOS1 with clinicopathological characteristics was performed to discuss using chi-square test. The prognostic value of ANOS1 expression was assessed using Kaplan–Meier survival analysis and Cox regression. The Spearman’s study was conducted to explore the relationship between ANOS1 expression, immunity, and EMT-related genes. Gene set enrichment analysis (GSEA) was utilized to determine the functional enrichment of ANOS1 in gastric cancer and the “pRRophetic”R package was utilized to determine the relationship between ANOS1 expression and drug sensitivity. TCGA data analysis has shown that ANOS1 was significantly overexpressed in advanced GC and high ANOS1 expression had a poor prognosis. The IHC analysis showed elevated ANOS1 levels in advanced GC tissues compared to the adjacent tissues. High ANOS1 expression was correlated with tumor infiltration, lymph node metastasis, TNM stage, and vascular invasion in advanced GC, indicating its role in tumor invasiveness and metastasis. Furthermore, research indicated that the expression of ANOS1 was inversely associated with E-cadherin levels in advanced GC. Kaplan–Meier analysis demonstrated that patients with high ANOS1 expression had poorer overall survival than those with low expression. Furthermore, ANOS1 was positively associated with EMT-related genes and correlated with 22 types of immune cell infiltration and 7 immune checkpoints. The patients with high expression levels of ANOS1 demonstrated sensitivity to 5-fluorouracil, dasatinib, and docetaxel. GSEA analysis revealed significant enrichment of ANOS1 in multiple oncogenic pathways, particularly extracellular matrix (ECM) receptor interactions, focal adhesion, hematopoietic cell lineage, chemokine signaling pathways, pathways in cancer, and transforming growth factor-β signaling pathway. ANOS1 may impact gastric cancer progression by regulating EMT, suggesting its dual utility as both a prognostic biomarker and a novel therapeutic target for GC intervention.

15 July 2025 in Molecular and Cellular Probes
Verified
Journal Article
Open access
LJLi Jin
Li Jin
LQLili Qian
Lili Qian
XZXin Zhang
Xin Zhang
TLTing Liu
Ting Liu
CPLX1 is a member of the complexin/Synaphin family. Studies have shown that CPLX1 is involved in tumor progression. However, the biological mechanism by which CPLX1 is involved in colorectal cancer (CRC) is unclear. TIMER and TCGA database provided difference expression of CPLX1 mRNA in pan-cancer and CRC. We collected 90 cases of CRC and adjacent normal tissues for immunohistochemistry (IHC) and investigated CPLX1 protein expression and its correlation with clinical information. Cox regression and Kaplan-Meier were conducted to determine prognostic value of CPLX1 expression. We utilized Spearman analysis to explore the association between CPLX1 and immune cell infiltration, immune checkpoints. We utilized GSEA to investigate the biological molecular function for CPLX1 in CRC. CPLX1 mRNA expression was elevated in several cancers, including CRC. Elevated CPLX1 protein expression was confirmed by IHC in CRC samples, and showed a positive association with T stage. The survival analysis demonstrated that CPLX1 overexpression was linked to a poorer overall survival (OS), disease-specific survival (DSS), and progress-free interval (PFI) for CRC. Time ROC analysis suggested that the survival rate of 1-year, 2-year and 3-year for OS, DSS, and PFI was above 0.5, suggesting a certain prognostic value in CRC. Cox regression considered CPLX1 expression as a good prognostic index for predicting OS, DSS, and PFI. Furthermore, CPLX1 expression was associated with immunity in CRC. Functional analysis showed that CPLX1 related genes had participation in Notch signaling pathway. CPLX1 was a latent prognostic and diagnostic marker for CRC and may also be a potential therapeutic target.

15 September 2025 in 3 Biotech
Verified
Journal Article
Open access
PDF file
XZXuan Zhou
Xuan Zhou
YSYifei Sun
Yifei Sun
QYQian Yang
Qian Yang
HLHong Li
Hong Li
YJYanxia Jiang
Yanxia Jiang
TLTing Liu
Ting Liu
EIF5A2, a key member of the EIF family, has not been extensively studied regarding its role and mechanism in pan-cancer. TCGA and GTEx analyses were performed to investigate the differential expression of EIF5A2 in tumors and normal tissues. cBioportal was used to investigate the gene alterations of EIF5A2 in tumors. We used Cox regression and Kaplan–Meier analyses to discuss the impact of EIF5A2 expression on prognosis. Quantitative real-time PCR (qRT-PCR) was used to detect EIF5A2 mRNA levels in 12 cases of fresh liver hepatocellular carcinoma (LIHC) and corresponding adjacent non-tumor tissues. Immunohistochemistry (IHC) was employed to evaluate the expression levels of EIF5A2 in 284 cases of LIHC as well as in adjacent non-tumorous tissues. Furthermore, the study explored the association between EIF5A2 expression and various clinicopathological parameters, along with its prognostic implications. Spearman correlation analysis was used to estimate the relationship between EIF5A2 expression and tumor mutation burden (TMB), microsatellite instability (MSI), and immunologic features. “pRRophetic”R package was utilized to obtain the sensitivity of common drugs. The Gene Set Enrichment Analysis (GSEA) was used to study the functional enrichment analysis of EIF5A2-related genes. EIF5A2 was overexpressed in most tumors using TCGA and GTEx databases. Cox regression analysis demonstrated that high EIF5A2 expression was associated with unfavorable overall survival (OS) and disease-specific survival (DSS) in head and neck squamous cell carcinoma (HNSC), brain lower grade glioma (LGG), and LIHC. The frequency of EIF5A2 gene alterations was the highest in lung squamous cell carcinoma (LUSC). EIF5A2 expression was associated with TMB, MSI, and immune cell infiltration in some tumors. We performed IHC and qRT-PCR to evaluate EIF5A2 expression in HCC and normal tissues, and found upregulation of EIF5A2 expression at the mRNA and protein levels in LIHC. There was a correlation between EIF5A2 expression and tumor size, tumor grade, and TNM stage in LIHC. Kaplan–Meier survival suggested that the overexpression EIF5A2 group had unfavorable outcomes in LIHC. EIF5A2 expression was correlated with immune cell infiltration in LIHC. The high EIF5A2 expression group was more sensitive to cisplatin, crizontinib, gemcitabine, and nilotinib in LIHC. High EIF5A2 expression was associated with several pathways, including cell cycle, proteasome, DNA replication, primary immunodeficiency and oocyte meiosis. EIF5A2 may serve as a potential prognostic marker and a latent focus for cancer immunological treatment.

29 June 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
JCJiamin Chen
Jiamin Chen
XKXiaoman Kang
Xiaoman Kang
XDXinghuan Ding
Xinghuan Ding
YDYuyang Dai
Yuyang Dai
LSLei Sun
Lei Sun
XZXingang Zhou
Xingang Zhou
Primary central nervous system lymphoma (PCNSL) refers to non-Hodgkin lymphoma (NHL) originating in the brain, eyes, spinal cord, and cerebrospinal fluid without the presence of lymphoma outside of the central nervous system